Sagredo O - Search Results

1

The endocannabinoid system in Huntington's disease.

Pazos MR, Sagredo O, Fernández-Ruiz J. Pazos MR, et al. Among authors: sagredo o. Curr Pharm Des. 2008;14(23):2317-25. doi: 10.2174/138161208785740108. Curr Pharm Des. 2008. PMID: 18781982 Review.

2

Therapeutic potential of the endocannabinoid system in the brain.

Ramos JA, González S, Sagredo O, Gómez-Ruiz M, Fernández-Ruiz J. Ramos JA, et al. Among authors: sagredo o. Mini Rev Med Chem. 2005 Jul;5(7):609-17. doi: 10.2174/1389557054368817. Mini Rev Med Chem. 2005. PMID: 16026307 Review.

3

Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.

Sagredo O, Ramos JA, Fernández-Ruiz J, Rodríguez ML, de Miguel R. Sagredo O, et al. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):313-7. doi: 10.1007/s00210-005-0026-1. Epub 2005 Dec 30. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16385404

4

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Sagredo O, et al. Eur J Neurosci. 2007 Aug;26(4):843-51. doi: 10.1111/j.1460-9568.2007.05717.x. Epub 2007 Aug 2. Eur J Neurosci. 2007. PMID: 17672854

5

Cannabinoids and neuroprotection in basal ganglia disorders.

Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. Sagredo O, et al. Mol Neurobiol. 2007 Aug;36(1):82-91. doi: 10.1007/s12035-007-0004-3. Epub 2007 Jun 23. Mol Neurobiol. 2007. PMID: 17952653 Review.

6

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Fernández-Ruiz J, et al. Among authors: sagredo o. Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S91-6. doi: 10.1016/j.mce.2008.01.001. Epub 2008 Jan 17. Mol Cell Endocrinol. 2008. PMID: 18291574 Review.

7

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Sagredo O, et al. Glia. 2009 Aug 15;57(11):1154-67. doi: 10.1002/glia.20838. Glia. 2009. PMID: 19115380 Free PMC article.

8

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Palazuelos J, et al. Among authors: sagredo o. Brain. 2009 Nov;132(Pt 11):3152-64. doi: 10.1093/brain/awp239. Epub 2009 Oct 5. Brain. 2009. PMID: 19805493

9

The endocannabinoid system as a target for the treatment of neuronal damage.

Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. Fernández-Ruiz J, et al. Among authors: sagredo o. Expert Opin Ther Targets. 2010 Apr;14(4):387-404. doi: 10.1517/14728221003709792. Expert Opin Ther Targets. 2010. PMID: 20230193 Review.

10

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Blázquez C, et al. Among authors: sagredo o. Brain. 2011 Jan;134(Pt 1):119-36. doi: 10.1093/brain/awq278. Epub 2010 Oct 7. Brain. 2011. PMID: 20929960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters